View Published SNOMED CT Subset Metadata

QOF Prescribable angiotensin-converting enzyme inhibitors

Subset Name :   
QOF Prescribable angiotensin-converting enzyme inhibitors
Subset Original Id :   
Subset Type :   
Realm Concept

Refset FSN :   
Quality and Outcomes Framework general practice extraction - angiotensin-converting enzyme inhibitors prescribable within general practice simple reference set (foundation metadata concept)
Refset Id :   
Refset Type :   

Subset Description :
All VMPs and AMPs associated with the following VTMs: Captopril, Cilazapril, Enalapril + Hydrochlorothiazide, Felodipine + Ramipril, Fosinopril, Hydrochlorothiazide + Quinapril, Imidapril, Lisnopril, Linsopril + Hydrochlorthiazide, Moexipril, Perindopril arginine, Perindopril arginine + Indapamide, Perindopril erbumine, Perindopril erbumine + Amlodipine, Perindopril erbumine + Indapamide, Perindopril tosilate, Perindopril tosilate + Indapamide, Quinapril, Ramipril, Trandolapril, Verapamil + Trandolapril, Co-zidocapt and Enalapril. The subset only includes VMPs and AMPs that have any of the following drug forms: Tablet, Capsule, Oral solution, Oral suspension, Modified release tablet, Modified release capsule and Powder. The subset also includes the VMPs Generic Tritace titration pack tablets and Generic Tritace titration pack capsules and associated AMPs. This subset, as currently published, supports the NHS England QOF business rules for 2018-2019. This subset may contain invalid concepts.


Subset Status :   
Subset Status Date :   
Mar 30, 2016
Owner (Organisation name) :   
NHS Digital

Purpose and Scope

Usage 1 :

Usage Type :    
Usage Description :    
Intended for secondary uses purposes. Management Information to support counts for establishing Quality and Outcomes Framework points used to determine Practice QOF payments. QOF Indicator Supported: Indicator CKD003: The percentage of patients on the Chronic Kidney Disease register with hypertension and proteinuria who are currently treated with an Angiotensin-Converting Enzyme Inhibitor (ACE-I) or Angiotensin RB NICE Guideline (where appropriate): These subsets are created using the XML format dm+d data and so within these subsets a small number of concepts are inactive (status 2 or 10) in the International Release. The origin of these inactive concepts is the native XML dm+d and they are now inactive in the new International Release due to natural movement and updating of the International Release content. Work is underway to update the dm+d concepts to the new International release identifiers; at this point this mismatch will be resolved. If using the dm+d in SNOMED CT format the International Release relationships will enable migration to the replacement concept. The subsets as published in the current release data are applicable to the QOF year 2018-2019.
Geographic Usage :    
Usage Category:    
 Quality Outcome Framework Prescribable

Scope :

Inclusion Criteria :   
Gender - not specified; Age group - any age; Sex - not specified
Subject Category :   
Prescribing; Chemicals and Drugs


Subset Release Category :   
UK Drug Extension
Language :   
Folder Name :   
File Name :   

Subset Licence Type :   
IHTSDO SNOMED CT® Licence; UKTC SNOMED CT® Licence; Open Government Licence

Metadata Version :   
Last Updated :   
Sep 7, 2018

Related Links

Subset download with descriptions :

UK Drug Extension releases